Meeting
2015 Genitourinary Cancers Symposium
Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC).
Authors
Jennifer Roberts
Tokai Pharma, Cambridge, MA
Jennifer Roberts , Reena Dhillon , Daniel T. Dransfield , Khalid Kevin Mamlouk , Karen J. Ferrante
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 259)
DOI
10.1200/jco.2015.33.7_suppl.259
Abstract #
259
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2016 ASCO Annual Meeting
Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2015 ASCO Annual Meeting
Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.
First Author: Mary-Ellen Taplin
Poster
2024 ASCO Genitourinary Cancers Symposium
Lipidomic profiling as a biomarker for prostate cancer diagnosis and response to enzalutamide (Enza).
First Author: Sara Bleve